Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors

Giovanni Caocci, Olga Mulas, Mario Annunziata, Luigiana Luciano, Elisabetta Abruzzese, Massimiliano Bonifacio, Ester Maria Orlandi, Francesco Albano, Sara Galimberti, Alessandra Iurlo, Patrizia Pregno, Nicola Sgherza, Bruno Martino, Gianni Binotto, Fausto Castagnetti, Antonella Gozzini, Monica Bocchia, Claudio Fozza, Fabio Stagno, Maria Pina SimulaFiorenza De Gregorio, Malgorzata Monika Trawinska, Luigi Scaffidi, Chiara Elena, Imma Attolico, Claudia Baratè, Daniele Cattaneo, Francesca Pirillo, Gabriele Gugliotta, Anna Sicuranza, Matteo Molica, Giorgio La Nasa, Robin Foà, Massimo Breccia

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Limited information is available regarding the rate of long-term cardiovascular (CV) mortality in chronic myeloid leukaemia (CML) patients treated with second- and third-generation tyrosine kinase inhibitors (2ndG/3rdG TKIs) in the real-life practice. Methods: We identified 656 consecutive CML patients treated with nilotinib, dasatinib, bosutinib and ponatinib. Results: The 15-year CV-mortality free survival was 93 ± 2.8%. Age ≥65 years (p = 0.005) and a positive history of CV disease (p = 0.04) were significantly associated with a lower CV-mortality free survival. CV disease accounted for 16.5% and 5% of potential years of life lost (PYLL) in male and female patients, respectively. The standard mortality ratio (SMR) following ischemic heart disease (IHD) was 3.9 in males and 3.8 in female patients, meaning an excess of IHD deaths observed, in comparison with the population of control. Conclusion. Prevention strategies based on CV risk factors, in particular in those patients with a previous history of CV disease, should be considered.

Original languageEnglish
JournalInternational Journal of Cardiology
DOIs
Publication statusAccepted/In press - Jan 1 2019

Keywords

  • a
  • Cardiovascular toxicity
  • Chronic myeloid leuk
  • emia
  • Ischemic heart disease
  • TKI

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors'. Together they form a unique fingerprint.

Cite this